A proposal for improvement of the first-line treatment of advanced diabetic retinopathy
Year: 2025
Type: article
Abstract: Diabetic retinopathy (DR) can be resulted from high blood glucose levels that may damage the retinal pigment epithelium, located between the vascular choroids and the neurosensory retina, which functions as a barrier. The first-line treatment of DR comprises an anti-vascular endothelial growth factor (anti-VEGF) compound such as Avastin (bevacizumab), Lucentis (ranibizumab) and Eylea (aflibercept). Some patients suffering from static condition of advanced DR need a treatment that will lead to improvement of the DR condition, e.g., reduction of abnormal blood vessels on the optic disc and preventing further ischemic optic neuropathy. Thus, a combined simultaneous treatment of an anti-VEGF compound such as Avastin, or a biosimilar version, and oral administration of fucoxanthin that has a protective effect on the retina, optionally together with vitamin A, is proposed for treating advanced DR.
Source: Technium BioChemMed
Author: Meyer Elazar
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4415140854
FWCI:
Cites:
Cited by:
Related to: